Table 1.
Clinical characteristics of all study subjects
| Variable, n (%) | |
|---|---|
| Age, median (year) | 64 (52–74) |
| Gender | |
| Male | 26 (83.9) |
| Female | 5 (16.1) |
| Smoking status | |
| Smoker/ex‐smoker | 23 (74.2) |
| Never smoker | 8 (25.8) |
| ECOG PS | |
| 0 | 25 (80.7) |
| 1 | 5 (16.1) |
| 2 | 1 (3.2) |
| Histology | |
| Adenocarcinoma | 20 (64.5) |
| Squamous cell carcinoma | 8 (25.8) |
| NSCLC NOS | 3 (9.7) |
| Staging | |
| IIIA | 8 (25.8) |
| IIIB | 21 (67.7) |
| IIIC | 2 (6.5) |
| EGFR mutation status | |
| Mutated EGFR | 4 (12.9) |
| Wild type | 19 (61.3) |
| Unknown | 8 (25.8) |
| ALK fusion status | |
| Positive | 1 (3.3) |
| Negative | 17 (54.8) |
| Unknown | 13 (41.9) |
| PD‐L1 TPS | |
| Positive (≥1%) | 14 (45.2) |
| Negative (<1%) | 6 (19.3) |
| Unknown | 11 (35.5) |
| Chemotherapy regimen | |
| Docetaxel plus cisplatin | 13 (41.9) |
| Vinorelbine plus cisplatin | 18 (58.1) |
| Dose of radiotherapy | |
| 60–66 Gy | 23 (74.2) |
| >66 Gy | 8 (25.8) |
| Timing of durvalumab initiation post‐CCRT, median (month) | 2.8 (1.8–3.7) |
| Total | 31 (100.0) |
ALK, anaplastic lymphoma kinase; CCRT, concurrent chemoradiation; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; NOS, not otherwise specified; PD‐L1, Programmed death‐ligand 1; TPS, tumor proportion score.